Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Initial Clinical Data Expected in the First Half of 2026 Initial Clinical Data Expected in the First Half of 2026